BPCR — Biopharma Credit Income Statement
0.000.00%
Last trade - 00:00- $1.06bn
- $1.05bn
- $157.78m
Annual income statement for Biopharma Credit, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 104 | 218 | 136 | 150 | 158 |
| Cost of Revenue | |||||
| Gross Profit | 88 | 184 | 110 | 124 | 132 |
| Selling / General / Administrative Expenses | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 18.9 | 35.8 | 27.3 | 27.9 | 27.9 |
| Operating Profit | 85 | 182 | 108 | 122 | 130 |
| Net Income Before Taxes | 85 | 182 | 108 | 122 | 130 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 85 | 182 | 108 | 122 | 130 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 85 | 182 | 108 | 122 | 130 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 85 | 182 | 108 | 122 | 130 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.062 | 0.134 | 0.083 | 0.1 | 0.114 |
| Dividends per Share | |||||
| Special Dividends per Share |